Industries > Pharma > Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028

Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis

PUBLISHED: 29 May 2018
PAGES: 196
PRODUCT CODE: PHA0312
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0312 Categories: , Tags: , ,

The global inflammatory bowel diseases drug market is estimated at $6.7bn in 2017 and $7.6bn in 2023. Biologic therapies held 57% share of the IBD market in 2017. The antibiotics segment of the IBD market is estimated to grow at a CAGR of 6.3% from 2018-2023.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 196-page report you will receive 141 charts– all unavailable elsewhere.

The 196-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2018-2028

Submarket forecasts from 2018-2028:
• Biologics
• Aminosalicylates
• Antibiotics
• Corticosteroids
• Immunomodulators

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028

• Revenue forecast from 2018-2028 for 17 leading products:
• Humira
• Remicade
• Lialda
• Asacol
• Pentasa
• Xifaxan
• Cimzia
• Tysabri
• Simponi
• Canasa/Salofalk
• Entyvio
• Apriso
• Medrol
• Neoral
• Entocort
• Uceris
• Azulfidine

• Revenue forecasts from 2018-2028 for 11 countries:
• US
• Japan
• Germany, France, UK, Spain and Italy (EU5)
• Brazil, Russia, India and China (BRIC)

• Discussions on research and development, including drug candidates in these classes:
• Interleukin (IL) inhibitors
• Cell-adhesion molecule (CAM) inhibitors
• TNF-alpha inhibitors
• Stem cell therapies
• JAK inhibitors
• Toll-like receptor agonists

• Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry

• Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the IBD market. Moreover, this report discusses factors that drive and restrain the IBD market.

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Buy our report today Global Inflammatory Bowel Diseases Drug Market Analysis: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn’s Disease, Ulcerative Colitis.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2018-2028


Latest Pharma news

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

READ

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

READ

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

READ

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2022-2032

The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.

13 September 2022

READ